PALISADE BIO, INC.

Analyst Reco. Palisade Bio, Inc.

Equities

SNCA

US6963894026

Market Closed - Nasdaq Other stock markets 21:30:01 06/05/2024 BST			5-day change	1st Jan Change
8.46 ^USD	+9.30%		+36.89%	-4.41%

05-01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
05-01	Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	11-17	MT
Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating	16/05/23	MT
Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $5	30/03/23	MT
Ladenburg Lowers Palisade Bio's Price Target to $1.50 From $5, Maintains Buy Rating	23/08/22	MT
Maxim Group Downgrades Palisade Bio to Hold From Buy	19/08/22	MT
Ladenburg Thalmann Starts Palisade Bio at Buy With $5 Price Target	02/02/22	MT
PALISADE BIO : Maxim Starts Palisade Bio at Buy With $7 Price Target	31/08/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer